Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 17, 2006

View Archived Issues

Zebularine improves survival in mouse model of T-cell lymphoma

LY-354740 prodrug, LY-544344, has greater behavioral effects in vivo

Glycyl-glutamine suppresses nicotine addiction in rats

N-Acetylcysteine well tolerated in cocaine-dependent individuals

OPT-80 shows efficacy in CDAD in phase IIa studies

Arimoclomol open-label extension study opens for ALS patients

NE-180 studied in phase I trial

OncoVEX(GM-CSF) studied for malignant melanoma, head and neck cancer

Advances in diagnostic tests for Alzheimer's disease

Acrux acquires rights to commercialize contraceptive spray

Novel Gb3 synthetic analogue demonstrates anti-HIV promise

Potent antimicrobial activity of a re-engineered vancomycin

Initiation of Veronate rolling BLA

AT-2101 receives orphan drug designation for Gaucher's disease

Novavax enters research collaboration with U. of Pittsburgh

Lilly and Boehringer Ingelheim amend Yentreve/AriClaim agreements

Phase I study of MEM-3454 completes dosing

sBLA filed for adjuvant Herceptin in early-stage HER2-positive breast cancer

Keryx inlicenses novel phosphate binder Zerenex

OSI begins phase I study with glucokinase activator PSN-010

Januvia NDA accepted for review

Accentia's IND for SinuNase on track

FDA lifts clinical hold on Tysabri in multiple sclerosis

Resistance profiling of a novel anti-V3 monoclonal antibody

ANA-380 achieves robust viral load reduction in lamivudine-resistant HBV patients

Novel agents reported for arthritis and other inflammatory disorders

Novel 5-HT2C receptor agonists emerge from Athersys R&D

Disruption of coordinated heart growth and angiogenesis contributes to heart failure

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...
Janssen Pharmaceutica reports new TMEM175 activators
BioWorld Science
Janssen Pharmaceutica NV has identified new endosomal/lysosomal proton channel TMEM175 activators that are potentially useful for the treatment of Parkinson’s...